ADT	androgen deprivation therapy.
ALP	alkaline phosphatase.
ARSIs	androgen receptor signaling inhibitors.
AR	androgen receptor.
AR-V	androgen receptor variant.
BCR	biochemical recurrence.
BEAMing	beads, emulsions, amplification, and magnets.
BPH	benign prostatic hyperplasia.
BSP	bone sialoprotein.
CDx	companion diagnostics.
cfDI	cell-free DNA integrity index.
cfDNA	cell-free DNA.
cfMeDIP-seq	cell-free methylated DNA immunoprecipitation sequencing.
cfMBD-seq	cell-free methyl CpG-binding domain protein sequencing.
CgA	chromogranin A.
CIN	chromosomal instability.
CRPC	castration-resistant prostate cancer.
CRPC-NE	neuroendocrine castration-resistant prostate cancer.
CTCs	circulating tumor cells.
ctDNA	circulating tumor DNA.
ctDNAF	circulating tumor DNA fraction.
DDR	DNA damage repair.
ddPCR	digital droplet PCR.
dMMR	mismatch repair deficiency.
FDG	fluorodeoxyglucose.
GGT	gamma-glutamyl transferase.
Hb	hemoglobin.
HRR	homologous recombination repair.
HSPC	hormone-sensitive prostate cancer.
LoD	limit of detection.
mCRPC	metastatic castration-resistant prostate cancer.
mHSPC	metastatic hormone-sensitive prostate cancer.
mPC	metastatic prostate cancer.
MRD	minimal residual disease.
MSI	microsatellite instability.
NE	neuroendocrine.
NEPC	neuroendocrine prostate cancer.
NGS	next-generation sequencing.
NSE	neuron-specific enolase.
OPG	osteoprotegerin.
OPN	osteopontin.
OS	overall survival.
PAP	prostatic acid phosphatase.
PARP	poly(adenosine diphosphate-ribose)polymerase.
PARPis	poly(adenosine diphosphate-ribose)polymerase inhibitors.
PC	prostate cancer.
PFS	progression-free survival.
PSA	prostate-specific antigen.
PSMA	prostate-specific membrane antigen.
rPFS	radiographic progression-free survival.
RRM2	ribonucleoside-diphosphate reductase subunit M2.
RCA	rolling circle amplification.
SLFN11	schlafen family member 11.
SRE	skeletal-related event.
TMB	tumor mutation burden.
TP	transperineal.
TR	transrectal.
TRACP	tartrate-resistant acid phosphatase.
TRUS	transrectal ultrasound.
WGS	whole-genome sequencing.